Merck & Co., Inc. Financial Highlights Package Fourth Quarter 2020 Table of Contents Table 1: GAAP P&L..........................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter......2 Table 2a: GAAP to Non-GAAP Reconciliation 4Q20 ........................3 Table 2b: GAAP to Non-GAAP Reconciliation Dec YTD 20.............4 Table 2c: GAAP to Non-GAAP Reconciliation 4Q19.........................5 Table 2d: GAAP to Non-GAAP Reconciliation Dec YTD 19 .............6 Table 3: Sales – Current Year and Prior Year by Quarter ...............7 Table 3a: Sales – U.S. / Ex- U.S. 4Q20 ............................................8 Table 3b: Sales – U.S. / Ex- U.S. Dec YTD 20. ................................9 Table 3c: Sales – Pharmaceutical Geographic Split .......................10 Table 4: Other (Income) Expense .................................................11 Table 5: Non-GAAP Reporting Changes........................................12 Tables 1 and 1a in the Financial Highlights Package reflect updated averages shares for 4Q 2020. -- 1 of 13 -- Sales 12,514 $ 11,868 $ 5% 47,994 $ 46,840 $ 2% Costs, Expenses and Other Cost of sales (1) 5,532 3,669 51% 15,485 14,112 10% Selling, general and administrative (1) 3,086 2,888 7% 10,468 10,615 -1% Research and development (1) 5,838 2,548 * 13,558 9,872 37% Restructuring costs (2) 309 194 59% 578 638 -9% Other (income) expense, net (1) (258) (223) 16% (886) 139 * (Loss) Income Before Taxes (1,993) 2,792 * 8,791 11,464 -23% Income Tax Provision (1) 99 428 1,709 1,687 Net (Loss) Income (2,092) 2,364 * 7,082 9,777 -28% Less: Net Income (Loss) Attributable to Noncontrolling Interests (1) 2 7 15 (66) Net (Loss) Income Attributable to Merck & Co., Inc. (2,094) $ 2,357 $ * 7,067 $ 9,843 $ -28% (Loss) Earnings per Common Share Assuming Dilution (3) (0.83) $ 0.92 $ * 2.78 $ 3.81 $ -27% Average Shares Outstanding Assuming Dilution (3) 2,530 2,559 2,541 2,580 Tax Rate (4) -5.0% 15.3% 19.4% 14.7% * 100% or greater (4) The effective income tax rates for the fourth quarter and the full year of 2020 include the unfavorable impact of charges for the acquisitions of VelosBio Inc. and OncoImmune for which no tax benefits were recognized. The effective income tax rates for the fourth quarter and the full year of 2019 include the unfavorable impact of a charge for the acquisition of Peloton Therapeutics, Inc. for which no tax benefit was recognized and the favorable impact of product mix. The effective income tax rate for the full year of 2019 also reflects a net tax benefit of $364 million related to the settlement of certain federal income tax matters. 4Q19 Full Year 2020 Full Year 2019 (1) Amounts include the impact of acquisition and divestiture-related costs, restructuring costs and certain other items. See accompanying tables for details. (2) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs. (3) Because the company recorded a net loss in the fourth quarter of 2020, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. The shares previously disclosed were the average common shares assuming dilution; however, the loss per common share was appropriately calculated based on the average common shares excluding potential dilutive shares. The shares figure has been updated to reflect the average common shares outstanding that were used in the loss per common share calculation. MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 GAAP % Change GAAP % Change 4Q20 1 -- 2 of 13 -- . . Sales 12,057 $ 10,872 $ 12,551 $ 12,514 $ 47,994 $ 10,816 $ 11,760 $ 12,397 $ 11,868 $ 46,840 $ 5% 2% Costs, Expenses and Other Cost of sales 3,312 3,159 3,481 5,532 15,485 3,052 3,401 3,990 3,669 14,112 51% 10% Selling, general and administrative 2,555 2,378 2,450 3,086 10,468 2,425 2,712 2,589 2,888 10,615 7% -1% Research and development 2,209 2,123 3,390 5,838 13,558 1,931 2,189 3,204 2,548 9,872 * 37% Restructuring costs 72 83 114 309 578 153 59 232 194 638 59% -9% Other (income) expense, net 71 (390) (312) (258) (886) 188 140 35 (223) 139 16% * Income (Loss) Before Taxes 3,838 3,519 3,428 (1,993) 8,791 3,067 3,259 2,347 2,792 11,464 * -23% Income Tax Provision 619 509 483 99 1,709 205 615 440 428 1,687 Net Income (Loss) 3,219 3,010 2,945 (2,092) 7,082 2,862 2,644 1,907 2,364 9,777 * -28% Less: Net Income (Loss) Attributable to Noncontrolling Interests - 8 4 2 15 (53) (26) 6 7 (66) Net Income (Loss) Attributable to Merck & Co., Inc. 3,219 $ 3,002 $ 2,941 $ (2,094) $ 7,067 $ 2,915 $ 2,670 $ 1,901 $ 2,357 $ 9,843 $ * -28% Earnings (Loss) per Common Share Assuming Dilution (1) 1.26 $ 1.18 $ 1.16 $ (0.83) $ 2.78 $ 1.12 $ 1.03 $ 0.74 $ 0.92 $ 3.81 $ * -27% Average Shares Outstanding Assuming Dilution (1) 2,547 2,536 2,538 2,530 2,541 2,603 2,588 2,572 2,559 2,580 Tax Rate 16.1% 14.5% 14.1% -5.0% 19.4% 6.7% 18.9% 18.7% 15.3% 14.7% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Because the company recorded a net loss in the fourth quarter of 2020, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. The shares previously disclosed were the average common shares assuming dilution; however, the loss per common share was appropriately calculated based on the average common shares excluding potential dilutive shares. The shares figure has been updated to reflect the average common shares outstanding that were used in the loss per common share calculation. 2Q 3Q 4Q Full Year 4Q Full Year 1Q 2Q 3Q 4Q Full Year 1Q MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2020 2019 % Change 2 -- 3 of 13 -- Cost of sales 5,532 $ 1,855 44 260 2,159 3,373 $ Selling, general and administrative 3,086 287 10 297 2,789 Research and development 5,838 13 16 3,161 3,190 2,648 Restructuring costs 309 309 309 - Other (income) expense, net (258) (2) (3) (5) (253) (Loss) Income Before Taxes (1,993) (2,153) (379) (3,418) (5,950) 3,957 Income Tax Provision (Benefit) 99 (423) (3) (22) (3) (61) (3) (506) 605 Net (Loss) Income (2,092) (1,730) (357) (3,357) (5,444) 3,352 Net (Loss) Income Attributable to Merck & Co., Inc. (2,094) (1,730) (357) (3,357) (5,444) 3,350 (Loss) Earnings per Common Share Assuming Dilution (0.83) $ (0.68) (0.15) (1.32) (2.15) 1.32 $ Tax Rate -5.0% 15.3% Only the line items that are affected by non-GAAP adjustments are shown. Table 2a GAAP Acquisition and Divestiture-Related Costs (1) Restructuring Costs (2) Certain Other Items (4) Adjustment Subtotal MERCK & CO., INC. GAAP TO NON-GAAP RECONCILIATION FOURTH QUARTER 2020 (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) (1) Amount included in cost of sales primarily reflects a $1.6 billion intangible asset impairment charge related to ZERBAXA and $274 million for the amortization of intangible assets recognized as a result of business acquisitions. Amount included in selling, general and administrative expenses reflects $244 million related to the company's planned spin-off of Organon & Co., and other acquisition and divestiture-related costs. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. (4) Amount included in cost of sales represents a charge for the discontinuation of COVID-19 vaccine development programs. Amount included in research and development represents the charges of $2.7 billion for the acquisition of VelosBio Inc., $462 million for the acquisition of OncoImmune and $45 million for the discontinuation of COVID-19 vaccine development programs. Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. 3 -- 4 of 13 -- Cost of sales 15,485 $ 2,718 175 260 3,153 12,332 $ Selling, general and administrative 10,468 935 47 982 9,486 Research and development 13,558 1 83 4,243 4,327 9,231 Restructuring costs 578 578 578 - Other (income) expense, net (886) 50 (20) 30 (916) Income Before Taxes 8,791 (3,704) (883) (4,483) (9,070) 17,861 Income Tax Provision (Benefit) 1,709 (671) (3) (81) (3) (303) (3) (1,055) 2,764 Net Income 7,082 (3,033) (802) (4,180) (8,015) 15,097 Net Income Attributable to Merck & Co., Inc. 7,067 (3,033) (802) (4,180) (8,015) 15,082 Earnings per Common Share Assuming Dilution 2.78 $ (1.19) (0.32) (1.65) (3.16) 5.94 $ Tax Rate 19.4% 15.5% Only the line items that are affected by non-GAAP adjustments are shown. Table 2b MERCK & CO., INC. GAAP TO NON-GAAP RECONCILIATION FULL YEAR 2020 (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) (4) Amount included in cost of sales represents a charge for the discontinuation of COVID-19 vaccine development programs. Amount included in research and development represents the charges for the acquisitions of VelosBio Inc. and OncoImmune, a charge for the discontinuation of COVID-19 vaccine development programs, and upfront payments related to license and collaboration agreements. GAAP Acquisition and Divestiture-Related Costs (1) Restructuring Costs (2) Certain Other Items (4) Adjustment Subtotal Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amount included in cost of sales primarily reflects a $1.6 billion intangible asset impairment charge related to ZERBAXA and $1.1 billion for the amortization of intangible assets recognized as a result of business acquisitions. Amount included in selling, general and administrative expenses reflects $710 million related to the company's planned spin-off of Organon & Co., approximately $95 million of costs related to the acquisition of ArQule, Inc., and other acquisition and divestiture-related costs. Amount included in other (income) expense, net, primarily reflects expenses related to an increase in the estimated fair value measurement of liabilities for contingent consideration, partially offset by royalty income related to the termination of the Sanofi- Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Acquisition and divestiture-related costs also includes a tax cost of $67 million, representing an adjustment to the tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition. 4 -- 5 of 13 -- Cost of sales 3,669 $ 325 90 415 3,254 $ Selling, general and administrative 2,888 44 1 45 2,843 Research and development 2,548 166 11 177 2,371 Restructuring costs 194 194 194 - Other (income) expense, net (223) (37) 7 (30) (193) Income Before Taxes 2,792 (498) (285) (18) (801) 3,593 Income Tax Provision (Benefit) 428 (55) (3) (49) (3) (76) (4) (180) 608 Net Income 2,364 (443) (236) 58 (621) 2,985 Net Income Attributable to Merck & Co., Inc. 2,357 (443) (236) 58 (621) 2,978 Earnings per Common Share Assuming Dilution 0.92 $ (0.17) (0.09) 0.02 (0.24) 1.16 $ Tax Rate 15.3% 16.9% Only the line items that are affected by non-GAAP adjustments are shown. Non-GAAP MERCK & CO., INC. GAAP TO NON-GAAP RECONCILIATION FOURTH QUARTER 2019 (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2c GAAP Acquisition and Divestiture-Related Costs (1) Restructuring Costs (2) Certain Other Items Adjustment Subtotal Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amount included in cost of sales primarily reflects $306 million of expenses for the amortization of intangible assets recognized as a result of business acquisitions, as well as $12 million of intangible asset impairment charges. Amount included in selling, general and administrative expenses primarily reflects integration, transaction and certain other costs related to business acquisitions and divestitures. Amount included in research and development expenses primarily reflects $164 million of in-process research and development (IPR&D) impairment charges. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. (4) Primarily reflects an $86 million tax benefit related to the reversal of tax reserves established in conjunction with the divestiture of Merck's Consumer Care business in 2014 as a result of the lapse in the statute of limitations. 5 -- 6 of 13 -- Cost of sales 14,112 $ 2,126 251 2,377 11,735 $ Selling, general and administrative 10,615 126 34 160 10,455 Research and development 9,872 145 4 993 1,142 8,730 Restructuring costs 638 638 638 - Other (income) expense, net 139 284 55 339 (200) Income Before Taxes 11,464 (2,681) (927) (1,048) (4,656) 16,120 Income Tax Provision (Benefit) 1,687 (493) (3) (155) (3) (380) (5) (1,028) 2,715 Net Income 9,777 (2,188) (772) (668) (3,628) 13,405 Less: Net (Loss) Income Attributable to Noncontrolling Interests (66) (89) (89) 23 Net Income Attributable to Merck & Co., Inc. 9,843 (2,099) (772) (668) (3,539) 13,382 Earnings per Common Share Assuming Dilution 3.81 $ (0.82) (0.30) (0.26) (1.38) 5.19 $ Tax Rate 14.7% 16.8% Only the line items that are affected by non-GAAP adjustments are shown. Table 2d MERCK & CO., INC. GAAP TO NON-GAAP RECONCILIATION FULL YEAR 2019 (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) (5) Primarily reflects a $364 million net tax benefit related to the settlement of certain federal income tax matters, an $86 million tax benefit related to the reversal of tax reserves established in conjunction with the divestiture of Merck's Consumer Care business in 2014 as a result of the lapse in the statute of limitations, and a $117 million tax charge related to the finalization of treasury regulations associated with the 2017 enactment of U.S. tax legislation. GAAP Acquisition and Divestiture-Related Costs (1) Restructuring Costs (2) Certain Other Items (4) Adjustment Subtotal Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amount included in cost of sales primarily reflects $1.4 billion of expenses for the amortization of intangible assets recognized as a result of business acquisitions, as well as $705 million of intangible asset impairment charges, including $612 million related to SIVEXTRO. Amount included in selling, general and administrative expenses primarily reflects integration, transaction and certain other costs related to business acquisitions and divestitures, including costs related to the acquisition of Antelliq Corporation. Amounts included in research and development expenses primarily reflect $172 million of in-process research and development (IPR&D) impairment charges, partially offset by a reduction in expenses related to a decrease in the estimated fair value measurement of liabilities for contingent consideration. Amount included in other (income) expense, net primarily reflects goodwill and intangible asset impairment charges related to certain businesses in the Healthcare Services segment and expenses related to an increase in the estimated fair value measurement of liabilities for contingent consideration, partially offset by royalty income related to the termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. (4) Amount included in research and development represents the charge related to the acquisition of Peloton Therapeutics, Inc. 6 -- 7 of 13 -- 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year Nom % Ex-Exch % Nom % Ex-Exch % TOTAL SALES (1) $12,057 $10,872 $12,551 $12,514 $47,994 $10,816 $11,760 $12,397 $11,868 $46,840 5 5 2 4 PHARMACEUTICAL 10,655 9,679 11,320 11,367 43,021 9,663 10,460 11,095 10,533 41,751 8 6 3 4 Oncology Keytruda 3,284 3,388 3,715 3,993 14,380 2,269 2,634 3,070 3,111 11,084 28 27 30 30 Alliance Revenue – Lynparza (2) 145 178 196 206 725 79 111 123 132 444 56 53 63 62 Alliance Revenue – Lenvima (2) 128 151 142 158 580 74 97 109 124 404 28 26 44 43 Emend 43 33 39 31 145 117 121 98 53 388 -42 -42 -63 -62 Vaccines (3) Gardasil / Gardasil 9 1,097 656 1,187 998 3,938 838 886 1,320 693 3,737 44 41 5 6 ProQuad / M-M-R II / Varivax 435 378 576 488 1,878 496 675 623 481 2,275 2 1 -17 -17 Pneumovax 23 256 117 375 339 1,087 185 170 237 334 926 1 17 18 RotaTeq 222 168 210 196 797 211 172 180 227 791 -14 -14 1 1 Vaqta 60 28 51 31 170 47 58 62 71 238 -56 -56 -29 -27 Hospital Acute Care Bridion 299 224 320 355 1,198 255 278 284 313 1,131 13 13 6 7 Noxafil 94 73 79 82 329 190 193 177 103 662 -20 -22 -50 -50 Prevymis 60 63 77 80 281 32 38 45 50 165 61 57 70 69 Primaxin 51 64 74 62 251 59 71 77 67 273 -8 -12 -8 -8 Cancidas 55 43 50 65 213 61 67 62 58 249 13 11 -14 -13 Invanz 64 43 51 53 211 72 78 57 57 263 -7 -4 -20 -16 Cubicin 46 32 39 36 152 88 67 52 50 257 -27 -28 -41 -40 Zerbaxa 37 32 43 19 130 26 27 35 32 121 -42 -42 8 10 Immunology Simponi 215 191 209 223 838 208 214 203 205 830 9 4 1 1 Remicade 88 73 82 88 330 123 98 101 89 411 -2 -5 -20 -20 Neuroscience Belsomra 79 84 81 83 327 67 76 80 83 306 1 -2 7 5 Virology Isentress / Isentress HD 245 196 205 211 857 255 247 250 223 975 -5 -6 -12 -11 Zepatier 55 39 28 45 167 114 108 83 66 370 -32 -32 -55 -54 Cardiovascular Zetia 145 137 103 98 482 140 156 147 146 590 -33 -36 -18 -19 Vytorin 53 39 47 43 182 97 76 57 54 285 -19 -20 -36 -34 Atozet 122 115 111 105 453 94 92 97 108 391 -3 -7 16 16 Alliance Revenue - Adempas (4) 53 79 83 65 281 42 51 50 60 204 8 8 38 38 Adempas (5) 56 57 55 53 220 48 53 57 57 215 -7 -11 3 2 Diabetes (6) Januvia 774 854 821 857 3,306 824 908 807 943 3,482 -9 -11 -5 -5 Janumet 503 490 506 472 1,971 530 533 503 475 2,041 -1 -1 -3 -2 Women's Health Implanon / Nexplanon 195 132 189 165 680 199 183 199 206 787 -20 -20 -14 -13 NuvaRing 63 63 58 53 236 219 240 241 179 879 -70 -70 -73 -73 Diversified Brands Singulair 155 100 82 124 462 191 160 152 195 698 -36 -38 -34 -34 Cozaar / Hyzaar 102 98 91 94 386 103 109 116 113 442 -17 -18 -13 -11 Arcoxia 70 65 68 54 258 75 75 72 67 288 -19 -18 -11 -8 Nasonex 71 49 41 57 218 96 72 58 67 293 -14 -13 -26 -24 Follistim AQ 41 44 50 57 193 57 63 62 58 241 -2 -4 -20 -20 Other Pharmaceutical (7) 1,194 1,103 1,186 1,228 4,709 1,082 1,203 1,149 1,183 4,615 4 2 2 3 ANIMAL HEALTH 1,214 1,101 1,220 1,168 4,703 1,025 1,124 1,122 1,122 4,393 4 6 7 10 Livestock 739 648 758 794 2,939 611 671 726 777 2,784 2 4 6 9 Companion Animals 475 453 462 374 1,764 414 453 396 345 1,609 8 9 10 11 Other Revenues (8) 188 92 11 (21) 270 128 176 180 213 696 -110 -45 -61 -22 2020 2019 4Q Full Year MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 (6) Total Diabetes sales were $1,353 million, $1,418 million, $1,405 million and $1,412 million in the first, second, third and fourth quarters of 2020 and $1,402 million, $1,480 million, $1,360 million and $1,472 million in the first, second, third and fourth quarters of 2019, respectively. (7) Includes Pharmaceutical products not individually shown above. (8) Other Revenues are comprised primarily of Healthcare Services segment revenues, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Total Vaccines sales were $2,155 million, $1,418 million, $2,521 million and $2,163 million in the first, second, third and fourth quarters of 2020 and $1,887 million, $2,037 million, $2,517 million and $1,928 million in the first, second, third and fourth quarters of 2019, respectively. (4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (5) Net product sales in Merck's marketing territories. 7 -- 8 of 13 -- 4Q 2020 4Q 2019 % Change 4Q 2020 4Q 2019 % Change 4Q 2020 4Q 2019 % Change TOTAL SALES (1) $12,514 $11,868 5 $5,631 $5,199 8 $6,882 $6,669 3 PHARMACEUTICAL 11,367 10,533 8 5,247 4,751 10 6,120 5,782 6 Oncology Keytruda 3,993 3,111 28 2,246 1,780 26 1,747 1,331 31 Alliance Revenue - Lynparza (2) 206 132 56 120 82 46 85 49 73 Alliance Revenue - Lenvima (2) 158 124 28 90 70 27 69 53 29 Emend 31 53 -42 10 -102 31 42 -27 Vaccines (3) Gardasil / Gardasil 9 998 693 44 546 252 117 452 441 2 ProQuad / M-M-R II / Varivax 488 481 2 345 358 -4 144 123 17 Pneumovax 23 339 334 1 249 251 -1 90 83 8 RotaTeq 196 227 -14 131 146 -10 65 81 -20 Vaqta 31 71 -56 25 28 -11 7 43 -85 Hospital Acute Care Bridion 355 313 13 172 152 13 183 162 13 Noxafil 82 103 -20 15 14 6 67 89 -24 Prevymis 80 50 61 32 24 32 48 25 90 Cancidas 65 58 13 5 2 198 60 56 7 Primaxin 62 67 -8 62 67 -8 Invanz 53 57 -7 2 * 50 57 -11 Cubicin 36 50 -27 10 13 -22 26 36 -30 Zerbaxa 19 32 -42 17 18 -7 2 14 -86 Immunology Simponi 223 205 9 223 205 9 Remicade 88 89 -2 88 89 -2 Neuroscience Belsomra 83 83 1 14 24 -42 69 59 18 Virology Isentress / Isentress HD 211 223 -5 83 95 -13 128 128 Zepatier 45 66 -32 22 23 -2 23 44 -47 Cardiovascular Zetia 98 146 -33 3 3 15 94 144 -34 Vytorin 43 54 -19 3 4 -27 40 49 -19 Atozet 105 108 -3 105 108 -3 Alliance Revenue - Adempas (4) 65 60 8 58 57 2 7 3 128 Adempas (5) 53 57 -7 53 57 -7 Diabetes (6) Januvia 857 943 -9 360 502 -28 497 441 13 Janumet 472 475 -1 115 127 -9 356 348 2 Women's Health Implanon / Nexplanon 165 206 -20 114 147 -22 50 59 -14 NuvaRing 53 179 -70 25 150 -83 28 29 -4 Diversified Brands Singulair 124 195 -36 4 5 -18 120 190 -37 Cozaar / Hyzaar 94 113 -17 4 8 -52 91 105 -14 Nasonex 57 67 -14 3 7 -63 55 60 -9 Follistim AQ 57 58 -2 24 22 9 33 36 -9 Arcoxia 54 67 -19 54 67 -19 Other Pharmaceutical (7) 1,228 1,183 4 410 377 9 818 809 1 ANIMAL HEALTH 1,168 1,122 4 361 341 6 807 781 3 Livestock 794 777 2 165 177 -7 629 600 5 Companion Animals 374 345 8 196 164 20 178 181 -2 Other Revenues (8) (21) 213 -110 23 107 -78 (45) 106 -142 * 200% or greater Sum of U.S. plus international may not equal global due to rounding. (3) Total Vaccines sales were $2,163 million and $1,928 million on a global basis in the fourth quarter of 2020 and 2019, respectively. MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES FOURTH QUARTER 2020 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3a Global U.S. International (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (5) Net product sales in Merck's marketing territories. (6) Total Diabetes sales were $1,412 million and $1,472 million on a global basis in the fourth quarter of 2020 and 2019, respectively. (7) Includes Pharmaceutical products not individually shown above. (8) Other Revenues are comprised primarily of Healthcare Services segment revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. 8 -- 9 of 13 -- Full Year 2020 Full Year 2019 % Change Full Year 2020 Full Year 2019 % Change Full Year 2020 Full Year 2019 % Change TOTAL SALES (1) $47,994 $46,840 2 $21,027 $20,519 2 $26,967 $26,321 2 PHARMACEUTICAL 43,021 41,751 3 19,449 18,953 3 23,572 22,798 3 Oncology Keytruda 14,380 11,084 30 8,352 6,305 32 6,028 4,779 26 Alliance Revenue - Lynparza (2) 725 444 63 417 269 55 308 176 75 Alliance Revenue - Lenvima (2) 580 404 44 359 239 50 220 165 34 Emend 145 388 -63 18 183 -90 127 205 -38 Vaccines (3) Gardasil / Gardasil 9 3,938 3,737 5 1,755 1,831 -4 2,184 1,905 15 ProQuad / M-M-R II / Varivax 1,878 2,275 -17 1,378 1,683 -18 500 592 -16 Pneumovax 23 1,087 926 17 727 679 7 359 247 46 RotaTeq 797 791 1 486 506 -4 311 284 9 Vaqta 170 238 -29 103 130 -21 67 108 -38 Hospital Acute Care Bridion 1,198 1,131 6 583 533 10 615 598 3 Noxafil 329 662 -50 42 282 -85 287 380 -24 Prevymis 281 165 70 119 84 41 162 81 101 Primaxin 251 273 -8 2 2 31 248 271 -9 Cancidas 213 249 -14 7 6 9 207 242 -15 Invanz 211 263 -20 9 30 -70 202 233 -13 Cubicin 152 257 -41 46 92 -49 106 165 -36 Zerbaxa 130 121 8 74 63 17 56 58 -2 Immunology Simponi 838 830 1 838 830 1 Remicade 330 411 -20 330 411 -20 Neuroscience Belsomra 327 306 7 81 92 -12 247 214 15 Virology Isentress / Isentress HD 857 975 -12 326 398 -18 531 576 -8 Zepatier 167 370 -55 60 118 -49 107 252 -58 Cardiovascular Zetia 482 590 -18 (1) 14 -108 483 575 -16 Vytorin 182 285 -36 12 16 -24 171 269 -37 Atozet 453 391 16 453 391 16 Alliance Revenue - Adempas (4) 281 204 38 259 194 33 22 10 130 Adempas (5) 220 215 3 220 215 3 Diabetes (6) Januvia 3,306 3,482 -5 1,470 1,724 -15 1,836 1,758 4 Janumet 1,971 2,041 -3 477 589 -19 1,494 1,452 3 Women's Health Implanon / Nexplanon 680 787 -14 488 568 -14 192 219 -12 NuvaRing 236 879 -73 110 742 -85 127 136 -7 Diversified Brands Singulair 462 698 -34 18 29 -40 444 669 -34 Cozaar / Hyzaar 386 442 -13 21 24 -13 365 418 -13 Arcoxia 258 288 -11 258 288 -11 Nasonex 218 293 -26 12 9 31 206 284 -27 Follistim AQ 193 241 -20 84 103 -18 109 138 -21 Other Pharmaceutical (7) 4,709 4,615 2 1,555 1,416 10 3,152 3,204 -2 ANIMAL HEALTH 4,703 4,393 7 1,484 1,306 14 3,219 3,086 4 Livestock 2,939 2,784 6 612 582 5 2,327 2,201 6 Companion Animals 1,764 1,609 10 872 724 20 892 885 1 Other Revenues (8) 270 696 -61 94 260 -64 176 437 -60 Sum of U.S. plus international may not equal global due to rounding. (3) Total Vaccines sales were $8,258 million and $8,368 million on a global basis for December YTD 2020 and 2019, respectively. MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES FULL YEAR 2020 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b Global U.S. International (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (5) Net product sales in Merck's marketing territories. (6) Total Diabetes sales were $5,588 million and $5,714 million on a global basis for December YTD 2020 and 2019, respectively. (7) Includes Pharmaceutical products not individually shown above. (8) Other Revenues are comprised primarily of Healthcare Services segment revenues, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. 9 -- 10 of 13 -- % Change % Change TOTAL PHARMACEUTICAL $10,655 $9,679 $11,320 $11,367 $43,021 $9,663 $10,460 $11,095 $10,533 $41,751 8 3 United States (1) 4,714 4,270 5,218 5,247 19,449 4,215 4,807 5,180 4,751 18,953 10 3 % Pharmaceutical Sales 44.2% 44.1% 46.1% 46.2% 45.2% 43.6% 46.0% 46.7% 45.1% 45.4% Europe (2) 2,543 2,196 2,549 2,709 9,997 2,335 2,301 2,304 2,373 9,314 14 7 % Pharmaceutical Sales 23.9% 22.7% 22.5% 23.8% 23.2% 24.2% 22.0% 20.8% 22.5% 22.3% China 846 811 990 888 3,534 725 745 898 773 3,141 15 13 % Pharmaceutical Sales 7.9% 8.4% 8.7% 7.8% 8.2% 7.5% 7.1% 8.1% 7.3% 7.5% Japan 789 847 805 847 3,288 779 900 894 921 3,494 -8 -6 % Pharmaceutical Sales 7.4% 8.8% 7.1% 7.5% 7.6% 8.1% 8.6% 8.1% 8.7% 8.4% Asia Pacific (other than China and Japan) 613 555 601 603 2,372 642 606 638 614 2,500 -2 -5 % Pharmaceutical Sales 5.8% 5.7% 5.3% 5.3% 5.5% 6.6% 5.8% 5.8% 5.8% 6.0% Eastern Europe/Middle East/Africa 490 416 419 365 1,689 343 388 423 423 1,577 -14 7 % Pharmaceutical Sales 4.6% 4.3% 3.7% 3.2% 3.9% 3.6% 3.7% 3.8% 4.0% 3.8% Latin America 419 399 477 474 1,768 427 523 534 429 1,914 10 -8 % Pharmaceutical Sales 3.9% 4.1% 4.2% 4.2% 4.1% 4.4% 5.0% 4.8% 4.1% 4.6% Canada 212 160 216 194 782 177 179 211 216 783 -10 0 % Pharmaceutical Sales 2.0% 1.7% 1.9% 1.7% 1.8% 1.8% 1.7% 1.9% 2.0% 1.9% Other (1) 29 25 45 40 142 20 11 13 33 75 21 89 % Pharmaceutical Sales 0.3% 0.3% 0.4% 0.4% 0.3% 0.2% 0.1% 0.1% 0.3% 0.2% 2020 2019 MERCK & CO., INC. PHARMACEUTICAL GEOGRAPHIC SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3c 4Q Full Year 1Q 2Q 3Q 4Q Full Year 1Q Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Alliance revenue related to Adempas attributable to the United States has been reclassified from Other. (2) Europe primarily represents all European Union countries and the European Union accession markets. 2Q 3Q 4Q Full Year 10 -- 11 of 13 -- OTHER (INCOME) EXPENSE, NET 4Q20 4Q19 Full Year 2020 Full Year 2019 Interest income (11) $ (50) $ (59) $ (274) $ Interest expense 206 220 831 893 Exchange losses 56 21 145 187 Income from investments in equity securities, net (1) (375) (119) (1,338) (170) Net periodic defined benefit plan (credit) cost other than service cost (80) (136) (339) (545) Other, net (54) (159) (126) 48 Total (258) $ (223) $ (886) $ 139 $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC. OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 11 -- 12 of 13 -- As Reported 2020 Impact of non-GAAP reporting changes As Recast 2020 Full Year 2020 Cost of sales $ 12,332 $ 719 $ 11,613 Selling, general and administrative 9,486 9,486 Research and development 9,231 11 9,220 Other (income) expense, net (916) (1,292) 376 Income Before Taxes 17,861 562 17,299 Income Tax Provision 2,764 186 2,578 Net Income 15,097 376 14,721 Net Income Attributable to Merck & Co., Inc. 15,082 376 14,706 Earnings per Common Share Assuming Dilution $ 5.94 $ 0.15 5.79 $ Tax Rate 15.5% 14.9% First Quarter 2020 Cost of Sales $ 2,948 $ 111 $ 2,837 Selling, General and administrative 2,266 2,266 Research and development 2,155 3 2,152 Other (income) expense, net 82 (87) 169 Income Before Taxes 4,606 (27) 4,633 Income Tax Provision 784 2 782 Net Income 3,822 (29) 3,851 Net Income Attributable to Merck & Co., Inc. 3,822 (29) 3,851 Earnings Per Common Share Assuming Dilution 1.50 $ (0.01) $ 1.51 $ Tax Rate 17.0% 16.9% Second Quarter 2020 Cost of Sales $ 2,852 $ 319 $ 2,533 Selling, General and administrative 2,204 2,204 Research and development 2,157 2 2,155 Other (income) expense, net (437) (511) 74 Income Before Taxes 4,096 190 3,906 Income Tax Provision 604 74 530 Net Income 3,492 116 3,376 Net Income Attributable to Merck & Co., Inc. 3,484 116 3,368 Earnings Per Common Share Assuming Dilution 1.37 $ 0.05 $ 1.32 $ Tax Rate 14.7% 13.6% Third Quarter 2020 Cost of Sales $ 3,158 $ 138 $ 3,020 Selling, General and administrative 2,228 2,228 Research and development 2,273 3 2,270 Other (income) expense, net (311) (346) 35 Income Before Taxes 5,203 205 4,998 Income Tax Provision 772 56 716 Net Income 4,431 149 4,282 Net Income Attributable to Merck & Co., Inc. 4,427 149 4,278 Earnings Per Common Share Assuming Dilution 1.74 $ 0.06 $ 1.68 $ Tax Rate 14.8% 14.3% Fourth Quarter 2020 Cost of Sales $ 3,373 $ 151 $ 3,222 Selling, General and administrative 2,789 2,789 Research and development 2,648 3 2,645 Other (income) expense, net (253) (348) 95 Income Before Taxes 3,957 194 3,763 Income Tax Provision 605 54 551 Net Income 3,352 140 3,212 Net Income Attributable to Merck & Co., Inc. 3,350 140 3,210 Earnings Per Common Share Assuming Dilution 1.32 $ 0.05 $ 1.27 $ Tax Rate 15.3% 14.6% Merck is providing certain 2020 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results and permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. MERCK & CO., INC. NON-GAAP REPORTING CHANGES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 5 Beginning in 2021, the Company will be changing the treatment of certain items for purposes of its non-GAAP reporting. Historically, Merck’s non-GAAP results excluded the amortization of intangible assets recognized in connection with business acquisitions, but did not exclude the amortization of intangibles originating from collaborations, asset acquisitions or licensing arrangements. In 2021, Merck’s non-GAAP results will no longer differentiate between the nature of intangibles amortization and will exclude all amortization of intangible assets. Also, beginning in 2021, Merck’s non-GAAP results will exclude gains and losses on investments in equity securities. These amounts are difficult to predict and can fluctuate significantly period to period affecting comparability of results. Non- GAAP results for the quarterly and annual periods of 2020 will be recast to conform to the new presentation. The table below provides details of the effects of these changes to the Company's non-GAAP results for the full year of 2020 and by quarter as will be presented in 2021 reporting. Non-GAAP Results 12 -- 13 of 13 --